[1] |
Peng ZW, Zhang YJ, Chen MS, et al. Radiofrenquecy ablation with or without transcatheter arterial chwmoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial[J]. J Clin Oncol, 2013, 31(4):426-432.
|
[2] |
Ni JY, Liu SS, Xu LF, et al. Transarterial chemoemblization combined with percutaneous radiofrequency ablation versus TACE and PREA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis[J]. J Cancer Res Clin Oncol, 2013, 139(4):653-659.
|
[3] |
Wang Y, Deng T, Zeng L, et al. Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a meta-analysis[J]. Hepatol Res, 2016, 46(1):58-71.
|
[4] |
Lee HY, Rhim H, Lee MW, et al. Early diffuse recurrence of hepatocellular carcinoma after percutaneous radiofrequency ablation: analysis of risk factors[J]. Eur Radiol, 2013, 23(1):190-197.
|
[5] |
Yamada S, Utsunomiya T, Morine Y, et al. Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy[J]. Ann Surg Oncol, 2014, 21(Suppl 3):S436-442.
|
[6] |
Yamashita S, Aoki T, Inoue Y, et al. Outcome of salvage hepatic resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy[J]. Surgery, 2015, 157(3): 463-472.
|
[7] |
Kishi Y, Shimada K, Nara S, et al. Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma[J]. World J Hepatol, 2014, 6(12):836-843.
|
[8] |
Cao JH, Zhou J, Zhang XL, et al. Meta-analysis on radiofrequency ablation in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma[J]. J Huazhong Univ Sci Technolog Med Sci, 2014, 34(5):692-700.
|
[9] |
Li HL, Ji WB, Zhao R, et al. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis[J]. World J Gastroenterol, 2015, 21(12): 3599-3606.
|
[10] |
Mise Y, Hasegawa K, Shindoh J, et al. The feasibility of third or more repeat hepatectomy for recurrent hepatocellular carcinoma[J]. Ann Surg, 2015, 262(2):347-357.
|
[11] |
Imai K, Beppu T, Chikamoto A, et al. Salvage treatment for local recurrence of hepatocellular carcinoma after local ablation therapy[J]. Hepatol Res, 2014, 44(14):E335-345.
|
[12] |
Lam VW, Ng KK, Chok KS, et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma[J]. J Am Coll Surg, 2008, 207(1):20-29.
|
[13] |
Chen L, Sun J, Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: current status[J]. Cancer Lett, 2016, 370(1):78-84.
|
[14] |
Cheng J, Li M, Lv Y. Sublethal heat treatment promotes epithelial-mesenchmal transition and enhances the malignant potential of hepatocellular carcionma[J]. Hepatology, 2014, 59(4):1650.
|
[15] |
Fernandes ML, Lin CC, Lin CJ, et al. Risk of tumor progression in early-stage hepatocellular carcinoma after radiofrequency ablation[J]. Br J Surg, 2009, 96(7):756-762.
|
[16] |
Kaseb AO, Shindoh J, Patt YZ, et al. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma[J]. Cancer, 2013, 119(18):3334-3342.
|
[17] |
Kokudo N, Hasegawa K, Akahane M, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2013 update (3rd JSH-HCC Guidelines)[J]. Hepatol Res, 2015, DOI: 10.1111/hepr.12464.
|
[18] |
Orimo T, Kamiyama T, Yokoo H, et al. Salvage hepatectomy for recurrent hepatocellular carcinoma after radiofrequency ablation and/or transcatheter arterial chemoembolization: a propensity score-matched analysis[J]. Dig Surg, 2018, 35(5):427-434.
|
[19] |
Kaibori M, Ishizaki M, Mastui K, et al. Predictor of microvascular invasion before hepatectomy for hepatocellular cacinoma[J]. J Surg Oncol, 2010, 102(5):462-468.
|